The United States was found to be a little bit thinner and healthier in 2023. Research findings show a decrease in obesity for the first time in a decade. Although this percentage is only 0.4%, it ...

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s.

The US Surgeon General released a report directly linking alcohol to cancer. A BI analysis of alcohol spending shows how ...

Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.

Adult obesity rates in the United States dropped from 46% in 2022 to 45.6% in 2023, according to the new study published in ...

(HealthDay News) — The mean body mass index (BMI) and prevalence of obesity declined in the United States in 2023, according to research published in JAMA Health Forum.

But without much media fanfare, the U.S. has recently experienced a boomlet in good health news. In May 2024, the U.S.

Novo Nordisk NVO shares have plunged 17.9% in a week due to poorer-than-expected efficacy data from a late-stage study of its ...

Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

but not for long Eli Lilly is still slightly behind Novo Nordisk in terms of market share of the incretin class in obesity in the United States, but this is more a reflection of the inability of ...

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

That’s a positive indicator, one doctor says, but developing healthier eating habits ‘would be much better than people just losing weight.’ ...